Gladius Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Gladius Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,000	Closed	-$442K	–	139
2021 Q1	$442K	Buy	+7,000	New	+$436K	0.02%	148
2019 Q4	–	Sell	-300,000	Closed	-$15.2M	–	176
2019 Q3	$15.2M	Buy	+300,000	New	+$14.1M	0.69%	30

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gladius Capital Management's BMY Position: Q2 2024 in Review

Gladius Capital Management sold out of Bristol-Myers Squibb (BMY) in Q2 2024, closing a stake of 727 shares — an estimated $39.4K sold.

Gladius Capital Management first reported a position in BMY in Q1 2021 and held it in 5 quarters. The position peaked at $630K in Q1 2022. 2,148 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

Gladius Capital Management reported no remaining Bristol-Myers Squibb position as of Q2 2024 after selling out during the quarter.
Gladius Capital Management sold 727 Bristol-Myers Squibb shares in Q2 2024, an estimated $39.4K.
Gladius Capital Management first reported a position in Bristol-Myers Squibb in Q1 2021 and held it in 5 quarters.
Gladius Capital Management's Bristol-Myers Squibb position peaked at $630K in Q1 2022.
2,148 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on Gladius Capital Management's 13F filing for Q2 2024, filed 18 Jul 2024.